Eugene Kim

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial

Howard West, Mark L. McCleland, Federico Cappuzzo et al. · Journal for ImmunoTherapy of Cancer · 2022 · 151 citations · Full text

Medicine, Oncology, Pharmacology +15

TRAF2 is an NF-κB-activating oncogene in epithelial cancers

Rhine R. Shen, Alicia Y. Zhou, Eugene Kim et al. · Oncogene · 2013 · 67 citations · Full text

Medicine, Cancer Biology, Oncology +12

The Novel Cytokine p43 Induces IL-12 Production in Macrophages via NF-κB Activation, Leading to Enhanced IFN-γ Production in CD4+ T Cells

Eugene Kim, Seung Hyun Kim, Sung‐Hoon Kim et al. · The Journal of Immunology · 2006 · 50 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study

Christopher R. Bolen, Magdalena Klánová, Marek Trněný et al. · Haematologica · 2019 · 47 citations · Full text

Medicine, Molecular Genetics, Oncology +17

The interplay among psychological distress, the immune system, and brain tumor patient outcomes

Sebastian Otto‐Meyer, Jan Lumibao, Eugene Kim et al. · Current Opinion in Behavioral Sciences · 2019 · 39 citations · Full text

Nursing, Immunology, Oncology +16